Rapport Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Rapport Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($111.48M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($78.31M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($34.79M) | Mar 11, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($125.10M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($83.06M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($36.18M) | Mar 11, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.79M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $60.94M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $28.00M | Mar 11, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($87.47M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($64.83M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($27.18M) | Mar 11, 2025 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $616.0K | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $2.41M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $1.64M | Mar 11, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $512.43M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $314.93M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $155.42M | Mar 11, 2025 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.78M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $9.51M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $14.48M | Mar 11, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $484.65M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $305.43M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | ($25.63M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | ($10.06M) | Mar 11, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($235.23M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($123.75M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($45.44M) | Mar 11, 2025 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.65M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $56.81M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $70.17M | Mar 11, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (23) | Mar 11, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (23) | Mar 11, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 47.77M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 36.58M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 4.17M | Mar 11, 2025 |